Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908048 · ClinicalTrials.gov registry record
Extracellular RNA Markers of Liver Disease and Cancer
A clinical trial of Hepatocellular Carcinoma and Cirrhosis, sponsored by Mayo Clinic.
- Active
- Registry status
- 1,810
- Enrollment target
- 4
- Study locations
NCT02908048 is a study of Hepatocellular Carcinoma and Cirrhosis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 1,810 participants, above the 245-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (639% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT02908048, a study of Hepatocellular Carcinoma and Cirrhosis, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 1,810 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
Conditions Studied
Interventions
- OTHER Blood samples
Study Locations (4)
Florida
- Mayo Clinic Florida - Jacksonville
Illinois
- The University of Chicago Medical Center - Chicago
Minnesota
- Mayo Clinic - Rochester
Virginia
- McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,810 participants |
| Start Date | 2014-07 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908048
The ClinicalTrials.gov registry entry for NCT02908048 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,810 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 245-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (639% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood samples is the first listed.
NCT02908048 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02908048 about?
NCT02908048 is a clinical study titled "Extracellular RNA Markers of Liver Disease and Cancer". The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
What is the current status of trial NCT02908048?
This trial is currently active not recruiting. The enrollment target is 1,810 participants. The study started on 2014-07. Estimated completion is 2026-07.
What conditions does trial NCT02908048 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Biliary Tract Cancer, Liver Diseases.
What interventions are being tested in trial NCT02908048?
The interventions under investigation include: Blood samples (OTHER).
Who is sponsoring clinical trial NCT02908048?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02908048 being conducted?
This trial has 4 study locations across Florida, Illinois, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.